Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular TargetsCorrado Pelaia, Giorgio Walter Canonica, Enrico Heffler et al.|Frontiers in Pharmacology|2022Cited by 157
Molecular Targets for Biological Therapies of Severe AsthmaCorrado Pelaia, Girolamo Pelaia, Claudia Crimi et al.|Frontiers in Immunology|2020Cited by 132
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudySanti Nolasco, Nunzio Crimi, Domenico Ciotta et al.|The Journal of Allergy and Clinical Immunology In Practice|2021Cited by 83
Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotypeCorrado Pelaia, Nunzio Crimi, Claudia Crimi et al.|Clinical & Experimental Allergy|2020Cited by 77
Tezepelumab: A Potential New Biological Therapy for Severe Refractory AsthmaCorrado Pelaia, Alessandro Vatrella, Giulia Pelaia et al.|International Journal of Molecular Sciences|2021Cited by 74